left
Hey There : )
right
company-image

Unlisted Shares

Anglo French Drugs & Industries Essentials

As of July 27, 2024, Anglo French Drug & Industries, Unlisted Shares are trading at ₹1320.00 per share, with a 52-week high of ₹2580 and 52-week low of ₹1320. The minimun lot size is 120 shares, and the shares are traded on NSDL and CDSL.

ISIN

INE570E01016

Face Value

₹ 10

Total Share

12,91,000

Total Income

₹ 102.51 undefined

Profit After Tax

₹ ****

EPS

₹ ****

P/E

****

P/B

****

Market Capitalisation

₹ 170.41 Cr

Enterprise Value

₹ ****

Book Value

₹ 879.95

Intrinsic Value

₹ ****

Earnings Yield

111.97 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Listed on Small Exchange

Cashflow - Operations

184.69

Cashflow - Financing

-₹ 11.7

Anglo French Drugs & Industries Growth

Compounded Sales Growth

1 Year

4 Year

7 Year

Compounded Profit Growth

1 Year

3 Year

7 Year

Return On Equity

2017

2020

2023

Highlights

image
  • About the Company: Anglo French Drugs & Industries Ltd. ("AFDIL"), is primarily involved in the manufacturing of pharmaceutical formulation, which primarily involves mixing various chemical compounds into active drugs/ingredients. The company is the formulator, supplier, and distributor of drugs and medicines across nutraceuticals, CNS, skin, and respiratory segments. From being an importer of medicines in 1923, the company has emerged as the manufacturer, marketer, and distributor of over 350 products across the world; over 100 years
image
  • Revenue Growth: The company's revenue has experienced a substantial decrease, reducing from ₹165 crore in FY22 to ₹102 crore in FY23, indicating a negative growth rate of -38%. Over the past years, the company's revenue has consistently increased, unlike FY23, which has represented a decrease. The company has achieved a compound annual growth rate (CAGR) of -2% from FY18 to FY23.
image
  • Notable Investors: The company has some prominent names on the captable such as Life Insurance Corporation of India holds a 7% and Ninaad Finance & Properties holds a 10% stake in the company.
image
  • Investment Thesis: Despite being in operation for six decades, the company's annual revenue remains below ₹170 Crores, indicating a potential efficiency concern. While the company recorded a profit (PAT) of ₹190 Crores in FY23, it's crucial to note that this figure includes a one-time gain of ₹299.68 Crores from the sale of brands. Excluding this exceptional item, the company incurred an operational loss of ₹40 Crores, highlighting underlying financial challenges. This raises inquiries about the company's overall financial performance and its capacity to effectively overcome current obstacles.

Business Rating

image

Managment

lock starlock starlock starlock starlock star
image

Accounting Practice

lock starlock starlock starlock starlock star
image

Profatibility

lock starlock starlock starlock starlock star
image

Solvency

lock starlock starlock starlock starlock star
image

Growth

lock starlock starlock starlock starlock star
image

Valuation

lock starlock starlock starlock starlock star

Overall Ratings

lock starlock starlock starlock starlock star

Recommendation

lock starlock starlock starlock starlock star

Our Team

Quantity

Invest

, Min. Investment: ₹